Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY have obtained the European Commission’s (EC) approval for a label expansion of their asthma drug Dupixent (dupilumab). The drug is now approved in the European Union (EU) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD), characterized by raised blood eosinophils. The approval of the COPD indication represents the sixth approved indication for Dupixent in the EU. The approval was mostly expected as the European Medicines Agency’s Committee for Medicinal Products for Human Use gave a positive opinion recommending the approval of Dupixent for COPD in May 2024. This latest EC approval is based on positive results from two late-stage studies, BOREAS and NOTUS, which evaluated the efficacy and safety of Dupixent in adults who were current or former smokers with moderate-to-severe COPD with evidence of type 2 inflammation. Results showed that Dupixent significantly reduced exacerbations and improved lung function and health-related quality of life. COPD is a respiratory disease that damages the lungs and causes progressive lung function decline. It is the fourth leading cause of death worldwide. Smoking and exposure to noxious particles are key risk factors for COPD. Per Regeneron and Sanofi, Dupixent is the first new treatment approach for COPD in more than a decade. The approval makes Dupixent a new treatment option for approximately 220,000 adults in the EU. While Sanofi records global net product sales of Dupixent and Kevzara, Regeneron records its share of profit in connection with the global sales of these drugs. The label expansion of Dupixent in the COPD indication should further boost sales of this blockbuster drug. Dupixent is a key top-line driver for both Sanofi and Regeneron. Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line. Regeneron’s shares have risen 19% year to date against the industry’s decline of 7.1%. Sanofi’s shares have lost 2.4% year to date against the industry’s 21.1% growth. Zacks Investment Research Image Source: Zacks Investment Research Zacks Investment Research Image Source: Zacks Investment Research During first-quarter 2024, Sanofi recorded €2.84 billion from Dupixent product sales, indicating a 25% year-over-year growth. Sanofi expects Dupixent to achieve about €13 billion in sales by this year’s end. Sanofi and Regeneron are striving to expand the drug’s label further. Both companies are evaluating the drug in a broad range of diseases driven by type II inflammation or other allergic processes, including chronic pruritus of unknown origin and bullous pemphigoid. However, the FDA has extended its review period for a regulatory filing seeking label expansion of Dupixent in the COPD indication by an additional three months. A final decision is now expected by Sep 27, 2024. The regulatory body had requested additional analyses on the efficacy of Dupixent in the BOREAS and NOTUS pivotal trials. The agency determined that this additional information, which was submitted, constituted a major amendment to the data filed in its earlier regulatory filing and extended the target action date. Regeneron and Sanofi are also evaluating itepekimab for the treatment of COPD. Zacks Rank and Stocks to Consider SNY currently carries a Zacks Rank #3 (Hold), while REGN has a Zacks Rank #4 (Sell). A couple of better-ranked stocks in the biotech sector are ALX Oncology Holdings ALXO and Minerva Neurosciences, Inc. NERV, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. ALX Oncology beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 8.83%. In the past 90 days, estimates for Minerva Neurosciences’ 2024 loss per share have narrowed from $3.57 to $1.89. The loss per share estimate for 2025 has narrowed from $4.54 to $3.60. NERV’s earnings beat estimates in one of the trailing four quarters and missed the same in the other three, the average negative surprise being 54.43%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN):Free Stock Analysis Report Sanofi (SNY):Free Stock Analysis Report Minerva Neurosciences, Inc (NERV):Free Stock Analysis Report ALX Oncology Holdings Inc. (ALXO):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...